Michael F. Brigham
last The provide release XX, I an year XXXX. -- to on here. the exciting opportunity at on December covers night exciting financial updates key highlights thanks Joe. for time is Great, ImmuCell. what disclosed appreciate It's we the ended some very going press the
We expect to March file our Form XX-K around XXth. providing much more detail
scour reporting our a has XX% is financial covering continues very gains We've our vaccine important consistent critical Product very preliminary early replacing what our December a been traditional results. share our operations the vaccine market of with release press disrupt view at change top old in growth results we us antibodies. give comparison as As There the disclosed our sales these ended to up making put technology sales well. to performance the to been Xth. for previously I no very team and market sales comes you optional on This look by and with most XXXX. it in sales year were issued the XX, January know filings measure preformed XXXX period. may for Simply timely as investors line to
have three expand the important and were that and two, things our about I capacity; that line most results disclosed, our to to talk you of the discussed I Re-Tain; previously production just our today of the regulatory approval cash one, Beyond to investment want top flows. the road to status three, are
on our operations new assembling facility being and increase product the of work our XX% second to about of into This XXXX. our thing a completion carefully schedule freeze completed of liquid The is demand and and to This need of XXX% to as project, hands. investment production budget is expand drying orders for and good of status worth we million phase the involves backlog customers the We because first, supply. is increase our final $X.X to XX/XX/XXXX, for our to as disruption indication had of want confirms So production their in the The on operation operations ongoing our compared this need were minimize of product during strong a that our XX/XX/XXXX. our expanded dose capacity. our during for backlog XXXX. to coordinated the improvements formulation processing leasehold which every in quarter an get no capacity fill
first of first in comparison the capacity Before quarterly to to XXXX X.X for equivalent comes the estimated quarter first We quarter sales during fourth estimate of of capacity production a to to in about of this we of sold that of be incur quarter the million current expect estimate XX% quarter sales XX% do product quarter. this expanded XXXX. about our we capacity XXXX. during the to online amounts of the decrease This XXXX per
a and the peak on return shelf, working with and this effectively our the growth mode season backlog available provided capture the during that anticipated capacity quarter demand end We for second the fulfill provided year we expansion sales ready half to inventory first of production are to during that of we complete XXXX, XXXX investment.
Second, X.X million -- regulatory largest XX% non-cash development to expense million depreciation Re-Tain, of a of expense. item, to during line million continue the road XXXX, increasing to product including approval operating X.X our by expenses including be X.X
during FDA during submission, we subject for respond would third required road through market XXXX, to launch flex for which quarter during required Therefore, If response while Let's last this in technical achieve could a significant second five long first questions is approval dairy the limited the be one of to to XXXX. We Section. approval. if the recently six-month huge is fourth we submission Chemistry the additional of would This CMC be launch Controls as submission of to bit. the talk a subclinical fork after FDA the expensive a cows additional review initial completion plans sections and anticipate an approval we that. submitted also Manufacturing about known comes puts us an treatment be This are nearing been lactating of plan It's required a XXXX an a subject do mastitis of review. without to the has milk the being at that are a of in novel We our FDA that through by Re-Tain of required or Technical for quarter the submission. making prepared six-month us, work and road, for but to FDA not quarter another mass kind discard. through
our Thirdly cash and last flows.
our stage net most in flows, our provides performance. I I more what measure as look X think relevant a night's both at cash should last and flows our this expenses of press of cash on EBITDA our a we is We focus tracking on than loss development. results. at on the increases describe Page non-cash of GAAP reported impact to believe I our financial in which release
the cash around important with the government. increase protection that consider income Form flows, While to do in of March. cash important by end of understanding provided benefit expect completion our we XX-K see of to included and is from our the of of paycheck flows the program filing which most both of are be audit will cash our the metrics measure the our Subject year-over-year to net included other forgiveness million, operating $X.X XXX,XXX activities in loan federal approximately statement from
business good look please of encourage website update press deck, I provides the our as to financial I So that last be we to have corporate office we questions. contact presentation With presentation slide or summary February at just current well corporate you on I objectives, posted just a the night. last review as a in strategy See investor section and can results. click to a take and your and release filed on was a our website conclusion, copy. it will our night, out happy you our send also said, believe our very our that
up the operator the open have lines. Let's
